Key Insights

Highlights

Treatment Research

5 treatments under study, led by Positron Emission Tomography

Related Conditions

Often studied with 5 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 1 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

1Total
Phase 1 (1)

Trial Status

Recruiting1

Clinical Trials (1)

Showing 1 of 1 trials
NCT06672705Phase 1RecruitingPrimary

Epcoritamab for the Treatment of Relapsed or Refractory Post Transplant Lymphoproliferative Disorders

Showing all 1 trials

Research Network

Common Treatments

  • Positron Emission Tomography1
  • Computed Tomography1
  • Biospecimen Collection1
  • Biopsy1
  • Epcoritamab1

Active Sponsors

  • AbbVie1
  • National Cancer Institute (NCI)1
  • Timothy Voorhees1
  • Genmab1

Top Investigators

Related Conditions

  • Refractory Monomorphic Posttransplant Lymphoproliferative Disorder1
  • Recurrent Monomorphic Posttransplant Lymphoproliferative Disorder1
  • Refractory Polymorphic Posttransplant Lymphoproliferative Disorder1
  • Ebvrelated Posttransplant Lymphoproliferative Disorder1
  • Recurrent Polymorphic Posttransplant Lymphoproliferative Disorder1

Activity Timeline